36LOW

EVE

EVEHEALTH FPO [EVE]
EVE Health Group Limited, together with its subsidiaries, engages in the development, retail, and commercialization of health and wellness, and pharmaceutical products. The company lead product is Dyspro, a proprietary pharmaceutical-grade formulation to address dysmenorrhea (menstrual pain); and Libbo, a proprietary pharmaceutical-grade oral dissolving film formulation for the treatment of erectile dysfunction. It also offers Lactobacillus rhamnosus Beebiotic MAP01, a proprietary strain to support digestive health and vitality. The company was formerly known as EVE Investments Limited. EVE Health Group Limited was incorporated in 2003 and is based in Subiaco, Australia.
Consumer Defensive · ASX Small Cap
$0.0200 +5.3%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical49
Catalyst72
Sentiment50
Fundamental42
Momentum25
Risk Gate45
Get alerts when EVE's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track EVE — Free

Active Signals

Bullish Signals

  • Stochastic just turned bullish from a low level — early reversal sign
  • Volume surging at 8.2x normal while price falls — heavy selling pressure
  • Beating the Small Ords index — relative strength of 1.12, so it's outpacing the pack
  • Volume-price trend suggests distribution — sellers may be sneaking out while price holds
  • Low cash runway (2 quarters) - dilution risk
  • Moderate P/S ratio (5.1x)
  • Revenue in sharp decline (-37%)
  • Near 52-week low (11% of range)
  • Micro-cap ($5-20M) - high risk
  • New substantial holder(s) (1)
  • CANSLIM S: Tight float (49%)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 50% over the past year
  • Low-priced stock risk ($0.020)
  • RBA hiking (-3pts)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-119%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -37% — the top line is shrinking
  • Overseas neutral (-1pts, S&P500 neutral, VIX 25)
  • Fading catalyst: strong catalyst but declining momentum
Ask Scout AI about EVE
"What's driving EVE's score?" "How does EVE compare to peers?" "Key risks for EVE?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

LOW Investor Presentation
NONE Change in substantial holding
NONE Application for quotation of securities - EVE
NONE Target Market Determination
HIGH Becoming a substantial holder
Announcement tone +3pts

Recent ASX Announcements

2026-03-25 Investor Presentation PRICE SENSITIVE
2026-03-25 Change in substantial holding
2026-03-22 Becoming a substantial holder
2026-03-22 Application for quotation of securities - EVE
2026-03-20 Target Market Determination

Key Metrics

$7.0M
Market Cap
484K
Avg Volume
8.2x
Vol Ratio
$0.02 — $0.04
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-77.7%
ROE
-119.1%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 49%
LLeader vs LaggardlaggardRS: -1
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Consumer Defensive

Ranked #45 of 46 · Sector avg: 48

View all Consumer Defensive signals →
Related Tickers
FRM 66CLV 58KME 58BXN 57GNC 55
Compare:EVE vs FRMEVE vs CLVEVE vs KME
Scout Pro — Deeper Analysis for EVE
Try Pro free for 30 days
Share this analysis

Track EVE and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required